Walden Biosciences Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
22
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
Walden Biosciences General Information
Description
Developer of a drug designed to treat kidney diseases such as chronic kidney disease, acute kidney injury, and others. The company specializes in manufacturing medicines for both rare and prevalent forms of kidney disease that target specific cells, enabling patients to get treatment options that target the kidney at the site of drug action.
Contact Information
Website
www.waldenbiosciences.comCorporate Office
- One Kendall Square
- Suite 7101
- Cambridge, MA 02139
- United States
Corporate Office
- One Kendall Square
- Suite 7101
- Cambridge, MA 02139
- United States
Walden Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 1. Early Stage VC (Series A) | 06-Oct-2020 | Completed | Generating Revenue |
Walden Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Walden Biosciences Patents
Walden Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025259719-A1 | Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease | Pending | 10-Jun-2024 | ||
| AU-2023339052-A1 | Dynamin activators | Pending | 09-Sep-2022 | ||
| EP-4583868-A2 | Dynamin activators | Pending | 09-Sep-2022 | ||
| EP-4583868-A4 | Dynamin activators | Pending | 09-Sep-2022 | ||
| US-20260070880-A1 | Dynamin activators | Pending | 09-Sep-2022 | C07D265/38 |
Walden Biosciences Signals
Walden Biosciences Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| ATEM Capital | Venture Capital | Minority | ||
| Eurofarma Ventures | Corporate Venture Capital | Minority | ||
| Mass General Brigham Ventures | Venture Capital | Minority | ||
| Pandect Bioventures | Venture Capital | Minority |
Walden Biosciences FAQs
-
When was Walden Biosciences founded?
Walden Biosciences was founded in 2020.
-
Where is Walden Biosciences headquartered?
Walden Biosciences is headquartered in Cambridge, MA.
-
What is the size of Walden Biosciences?
Walden Biosciences has 22 total employees.
-
What industry is Walden Biosciences in?
Walden Biosciences’s primary industry is Drug Discovery.
-
Is Walden Biosciences a private or public company?
Walden Biosciences is a Private company.
-
What is Walden Biosciences’s current revenue?
The current revenue for Walden Biosciences is .
-
How much funding has Walden Biosciences raised over time?
Walden Biosciences has raised $51M.
-
Who are Walden Biosciences’s investors?
ARCH Venture Partners, ATEM Capital, Eurofarma Ventures, Mass General Brigham Ventures, and Pandect Bioventures are 5 of 6 investors who have invested in Walden Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process